Ten patient and provider groups, representing millions of Americans, issued the following statement in response to the release of the nonpartisan Congressional Budget Office's (CBO) scores of two pieces of health care reform legislation currently being considered by the U.S. Senate.
- About the CF Foundation
- Public Policy
- Health Care Reform
- Our Research Approach
- Clinical Trials
- Cystic Fibrosis Foundation Therapeutics (CFFT)
- Genetic Therapies
- Drug Pipeline
- CFTR Modulators
- Care Centers
- North American CF Conference
- Coronavirus (COVID-19)
- Get Involved
- Infection Prevention and Control
- Adult Care
- Patient Assistance
- Researcher Resources
- (-) Our Advocacy Work
Cost effectiveness analysis must be used carefully and as part of a comprehensive evaluation of the value a treatment, such as highly effective modulators, provide to people living with cystic fibrosis.
Twelve patient/consumer groups urge senate to reject the bill.
Responding to the Trump administration's recent decision to freeze risk adjustment payments, the Cystic Fibrosis Foundation joined 13 other nonpartisan patient groups to voice disappointment in the latest administrative efforts to undermine adequate and affordable health care for people with pre-existing conditions.
Patient and provider groups urge the Senate to work together in a bipartisan fashion to ensure that Americans have access to affordable health care.
Eight organizations issue statement criticizing Upton Amendment.
Patient and provider groups urge safeguard for the health and lives of millions of Americans with a bipartisan approach to reform.
Today, the Senate released a new draft of the Better Care Reconciliation Act (BCRA), including an amendment that would allow insurance companies to offer plans not in compliance with critical patient protections in current law.
The organizations urge continued protections for patients.
A cystic fibrosis diagnosis must not disqualify an individual from life-saving care.